Lumida
/CI
⌘K
Cigna Group

Cigna Group

CI
$281.45USD↓-0.84%-2.37 today

MARKET CAP

74.5B

P/E (TTM)

9.1x

FWD P/E

8.7x

DAY RANGE

$280 – $290

52W RANGE

$240
$315

AI Summary

Stalk
TrimMedium

CI has broken below its consolidation support with a terminal Support Failure pattern, accelerating below the 9- and 21-day EMAs. The high Stage Transition Risk and lack of short-term exhaustion invalidate the prior bullish posture, shifting the medium-term bias to bearish. Execution should be deferred until a retest of the broken support/EMA zone offers a clean rejection setup for trimming the position.

  • ↑Q1 revenue $68.5B (+9% YoY) and adjusted EPS $7.79 (+16%)
  • ↑Raised full-year adjusted EPS guidance to at least $30.35
  • ↓Negative profitability score flags margin risk in pharmacy benefit services
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Cigna Group (NYSE: CI) is a leading global health service organization specializing in integrated health solutions, including health insurance, pharmacy benefit management, and innovative specialty care services through its Evernorth platform. Cigna operates in a regulatory-intensive healthcare environment, strategically focusing on affordability and personalized healthcare solutions as it navigates increasing market competition and shifting consumer demands.

Bull says

  • ↑Q1 revenue $68.5B (+9% YoY) and adjusted EPS $7.79 (+16%)
  • ↑Raised full-year adjusted EPS guidance to at least $30.35
  • ↑Evernorth specialty care drove 20% adjusted earnings growth in Q1
  • ↑Exited individual exchange market to focus on core high-growth segments
  • ↑Strong earnings yield and buyback yield support undervaluation thesis
  • ↑Operating cash flow $1.1B and debt-to-capital at 42.3% show solid liquidity

Bear says

  • ↓Negative profitability score flags margin risk in pharmacy benefit services
  • ↓Weak growth outlook after exchange exit suggests scaling challenges
  • ↓High short interest and weak quality score reflect investor skepticism
  • ↓Regulatory changes around pharmacy benefits and pricing may reduce margins
  • ↓Shrinking individual exchange segment and elevated costs could erode earnings
  • ↓Underlying growth and profitability headwinds may offset valuation support

Investment themes with CI

High Dividend Yield↑ +0.32%

Companies paying above-average dividends

AVGO · JPM · XOM
Health Care Providers↓ -0.61%

UNH · CVS · HCA

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 04-30-2026neutral

Transcript signals

Bull points

  • We're really pleased with the performance of the overall Cigna Healthcare business and also excited to be able to raise the guide for the year based on what we're seeing so far, which includes an appropriate degree of prudence for the balance of the year.
  • we started the year with strong results across both Evernote Health Services and Cigna Healthcare. Overall, Evernote earnings were slightly ahead of expectations. This was driven by the strength of our specialty and care services businesses, which delivered adjusted earnings growth of 20% in the quarter, reflecting continued attractive volume growth.
  • As a result of this combined strength, we are pleased to increase our earnings guidance for the year to at least $30.35 per share.

Bear points

  • the ongoing tension here is affordability versus employee and family member satisfaction. So employers know this is a very popular benefit. They also know that it's a net cost right now to their overall health care programs.
  • we are planning to exit our individual exchange business at the end of this year. We did not make this decision lightly and appreciate the importance of ensuring patients have continuity through the transition.
  • Our first quarter results reflect previously discussed impacts of large client renewals and investments as we progress toward our transformative new rebate-free model, aptly named Signature.
Read full transcript analysis ›